7Baggers
 Published on: 2025-11-16 10:13:27  newser.com Sun, 16 Nov 2025 16:13:27 GMT
 instil bio narrows losses and impresses wall street analysts  Finimize Fri, 14 Nov 2025 10:49:14 GMT
 Instil Bio Narrows Losses And Impresses Wall Street Analysts  Finimize Thu, 13 Nov 2025 12:55:21 GMT
 Instil Bio reports Q3 EPS ($1.75) vs ($2.55) last year  TipRanks Thu, 13 Nov 2025 12:24:48 GMT
 instil bio, inc. sec 10-q report  TradingView Thu, 13 Nov 2025 12:13:00 GMT
 Instil Bio Q3 net loss per share narrows  MarketScreener Thu, 13 Nov 2025 12:12:41 GMT
 Published on: 2025-11-13 02:01:06  newser.com Thu, 13 Nov 2025 08:01:06 GMT
 published on: 2025-11-11 07:02:30  newser.com Tue, 11 Nov 2025 13:02:30 GMT
 The Technical Signals Behind (TIL) That Institutions Follow  news.stocktradersdaily.com Mon, 10 Nov 2025 12:56:03 GMT
 published on: 2025-11-09 03:11:23  newser.com Sun, 09 Nov 2025 09:11:23 GMT
 published on: 2025-11-06 05:09:47  newser.com Thu, 06 Nov 2025 11:09:47 GMT
 published on: 2025-11-02 21:10:11  newser.com Mon, 03 Nov 2025 02:10:11 GMT
 published on: 2025-10-31 05:53:37  newser.com Fri, 31 Oct 2025 10:53:37 GMT
 published on: 2025-10-30 01:26:11  newser.com Thu, 30 Oct 2025 06:26:11 GMT

Instil Bio, Inc.
(NASDAQ:TIL) 

TIL stock logo

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, ...

Founded: 2018
CEO: Bronson Crouch  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends